EyePoint Pharmaceuticals Inc
EYPT
Company Profile
Business description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Contact
480 Pleasant Street
Suite A-210
WatertownMA02472
USAT: +1 617 926-5000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
144
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,614.20 | 40.80 | 0.48% |
| CAC 40 | 7,942.42 | 58.79 | 0.75% |
| DAX 40 | 24,036.11 | 101.13 | 0.42% |
| Dow JONES (US) | 42,677.24 | 114.83 | -0.27% |
| FTSE 100 | 8,781.12 | 81.81 | 0.94% |
| HKSE | 23,807.13 | 125.65 | 0.53% |
| NASDAQ | 19,142.71 | 72.75 | -0.38% |
| Nikkei 225 | 37,401.59 | 127.90 | -0.34% |
| NZX 50 Index | 12,697.71 | 53.48 | 0.42% |
| S&P 500 | 5,940.46 | 23.14 | -0.39% |
| S&P/ASX 200 | 8,390.30 | 47.00 | 0.56% |
| SSE Composite Index | 3,393.49 | 13.02 | 0.39% |